Maggiore Umberto, Cristol Jean-Paul, Canaud Bernard, Dupuy Angel Marie, Formica Marco, Pozzato Marco, Panichi Vincenzo, Consani Cristina, Metelli Maria Rita, Sereni Luisa, De Nitti Concetta, David Salvatore, Tetta Ciro
Department of Internal Medicine, University of Pisa, Italy.
J Lab Clin Med. 2005 Jun;145(6):305-8. doi: 10.1016/j.lab.2005.03.002.
Chronic inflammation has been repeatedly reported in individuals undergoing hemodialysis. C-reactive protein (CRP) is considered a marker of chronic inflammation, as well as a mediator of the atherosclerotic process. Clinical and epidemiologic studies are based on plasma values obtained with the use of various automated methods. Our aim was to test 3 commercially available methods and compare the values obtained with the use of these tests in a population of individuals undergoing hemodialysis. We compared the following methods: immunoturbidimetry (AU2700 biochemistry analyzer; Olympus, Rungis, France) laser nephelometry (Behring Diagnostics, Marburg, Germany), and nephelometry (Beckman Instruments, Fullerton, Calif. The 3 methods were used in 3 different centers: Montpellier, France; and Pisa and Turin, Italy, respectively. We prepared samples for the estimation of imprecision values (ie, coefficient of variation [CV]) from the plasma of normal patients by adding purified C-reactive protein at concentrations ranging from 2.6 to 180 mg/L for intraassay variation and concentrations of 0, 1, 2, 3, 5, 10, 20, 50, 100, 150, and 180 mg/L for interassay variation. Intraassay imprecision was determined with the use of 10 replicate analyses on the same sample of the same day. We assessed interassay imprecision using the same sample, divided into aliquots and measured on 5 consecutive days. Agreement between methods was assessed on predialysis serum samples collected from patients with stable chronic kidney disease who were undergoing long-term hemodialysis at the 3 different centers (Montpellier,192; Pisa, 56; Turin,98). Serum was separated from the red cells and stored in 3 aliquots at -70 degrees C until it could be analyzed. Samples were thawed only once, circulated among the 3 centers, and each tested with all 3 of the methods. The Beckman method yielded the most precise results, with intraassay CVs ranging from 1 to 2 and interassay CVs ranging from 1 to 4. The Behring method was the least precise, with intraassay and interassay CVs ranging from 12 to 15 and 7 to 16, respectively. The results of the Olympus method fell between those of the other 2 methods. Agreement between the results of the Olympus and Behring methods was satisfactorily. The Beckman and Olympus methods yielded, on average, similar results over the entire range of CRP values. We detected significant disagreement between the Beckman method and the other 2 methods, obtaining results 10 to 100 times lower with the Beckman method. This became evident in terms of kappa-statistics. Our findings emphasize the need for careful assessment of the methods used to detect CRP in serum samples. Failure to do so may ultimately have a negative impact on the real relevance of CRP as a marker and on the role of chronic implication particularly in epidemiologic studies.
慢性炎症在接受血液透析的个体中屡有报道。C反应蛋白(CRP)被认为是慢性炎症的标志物,也是动脉粥样硬化进程的介质。临床和流行病学研究基于使用各种自动化方法获得的血浆值。我们的目的是测试3种市售方法,并比较在接受血液透析的个体群体中使用这些测试所获得的值。我们比较了以下方法:免疫比浊法(AU2700生化分析仪;奥林巴斯,法国伦吉斯)、激光散射比浊法(贝林诊断公司,德国马尔堡)和散射比浊法(贝克曼仪器公司,加利福尼亚州富勒顿)。这3种方法分别在3个不同中心使用:法国蒙彼利埃;意大利比萨和都灵。我们通过添加浓度范围为2.6至180mg/L的纯化C反应蛋白来制备用于估计不精密度值(即变异系数[CV])的样本,用于批内变异,以及浓度为0、1、2、3、5、10、20、50、100、150和180mg/L用于批间变异。批内不精密度通过在同一天对同一样本进行10次重复分析来确定。我们使用同一样本评估批间不精密度,将其分成几份并连续5天进行测量。在3个不同中心(蒙彼利埃19例;比萨56例;都灵98例)对患有稳定慢性肾病且正在接受长期血液透析的患者采集的透析前血清样本进行方法间一致性评估。血清与红细胞分离,并分成3份储存在-70℃直至可以进行分析。样本仅解冻一次,在3个中心之间流转,并使用所有3种方法进行检测。贝克曼方法产生的结果最精确,批内CV范围为1至2,批间CV范围为1至4。贝林方法最不精确,批内和批间CV分别为12至15和7至16。奥林巴斯方法的结果介于其他2种方法之间。奥林巴斯和贝林方法的结果之间的一致性令人满意。在整个CRP值范围内,贝克曼和奥林巴斯方法平均产生相似的结果。我们检测到贝克曼方法与其他2种方法之间存在显著差异,贝克曼方法获得的结果低10至100倍。这在kappa统计方面变得很明显。我们的研究结果强调需要仔细评估用于检测血清样本中CRP所使用的方法。不这样做最终可能会对CRP作为标志物的实际相关性以及慢性影响的作用产生负面影响,特别是在流行病学研究中。